The CH50 test is a functional assay that measures the total lytic activity of the entire classical complement cascade—from C1 activation through C9 membrane attack complex formation. Its biological principle relies on the ability of patient serum to lyse antibody-coated sheep red blood cells, a process that requires every classical pathway component to be present and functional. The key biological reagents are sensitized sheep erythrocytes (EA complexes) created by coating sheep red blood cells with rabbit anti-SRBC antibodies, and the patient’s serum itself, which serves as the source of complement proteins.
The CH50 assay evaluates classical complement pathway integrity by quantifying the serum dilution that lyses exactly 50% of a standardized population of antibody-sensitized sheep red blood cells. It requires only two critical biological components: antibody-coated target cells and the serum sample, making it a straightforward yet powerful screening tool for complement deficiencies.
The Biological Principle of the CH50 Test
How the Classical Complement Cascade Drives Lysis
The classical pathway is triggered when C1q binds to the Fc region of antibodies (IgM or specific IgG subclasses) that are already immobilized on a target surface. In the CH50 assay, rabbit anti-sheep red blood cell antibodies (hemolysin) coat the sheep erythrocytes, forming erythrocyte-antibody (EA) complexes.
This immune complex activates C1, which then cleaves C4 and C2 to assemble the classical C3 convertase (C4b2a). The cascade proceeds through C3 cleavage, C5 activation, and the sequential assembly of C6, C7, C8, and multiple C9 molecules to form the membrane attack complex (MAC). The MAC inserts into the erythrocyte membrane, creating pores that disrupt osmotic balance and cause osmotic lysis of the target cell.
The Significance of the 50% Hemolysis Endpoint
The assay does not rely on complete lysis. Instead, it measures the serum dilution at which 50% of the sensitized erythrocytes are lysed. This midpoint lies on the steepest part of the dose-response curve, providing the greatest sensitivity to small variations in complement activity. Released hemoglobin is quantified spectrophotometrically at 412 nm, and the reciprocal of the dilution giving 50% lysis yields the CH50 value.
If any component of the classical cascade (C1 through C9) is absent, severely depleted, or functionally inactive, the cascade stalls and lysis fails to reach 50%, resulting in a low CH50 reading.
Key Biological Reagents Required for Assay Formulation
Sensitized Sheep Red Blood Cells (EA Complexes)
The target cell is the sheep red blood cell (SRBC), selected for its consistent availability and reproducible lysis characteristics. SRBCs are incubated with rabbit anti-SRBC antibodies (hemolysin) to create stable EA complexes. This sensitization step is critical: without antibody coating, the classical pathway cannot initiate.
The quality of the hemolysin—its titer, affinity, and subclass—directly impacts assay performance. For IVD manufacturers, controlled sensitization protocols and stabilized erythrocyte reagents ensure lot-to-lot consistency.
Patient Serum as the Complement Source
The serum sample provides all the necessary native complement proteins (C1–C9). The assay requires that the complement system in the serum be fully functional and not inactivated by improper handling. Blood must be collected, clotted, and separated promptly; storage at −80°C is typical to preserve heat-labile components.
No external complement proteins are added—the CH50 test reflects the in vivo functional capacity of the patient’s own complement system.
Interpreting CH50 in a Diagnostic Workflow
Distinguishing Classical vs. Alternative Pathway Defects
A low CH50 result indicates either a classical pathway component deficiency or a shared terminal pathway defect. To pinpoint the lesion, CH50 is interpreted alongside AH50, which measures alternative pathway function. The pattern of results reveals the likely defect:
- Low CH50, normal AH50: Defect in early classical components (C1q, C1r, C1s, C4, C2).
- Normal CH50, low AH50: Defect in alternative pathway factors (Factor B, Factor D, Properdin).
- Low CH50 and low AH50: Terminal pathway deficiency (C3, C5–C9) or severe systemic consumption.
This logic guides reflex testing with quantitative immunoassays for individual proteins like C3, C4, C1q, and Factor B, turning functional screening into precise molecular diagnosis.
The Role of Divalent Cations in Pathway Specificity
Classical pathway activation requires both calcium (Ca²⁺) and magnesium (Mg²⁺). In alternate pathway AH50 assays, a buffer containing EGTA chelates calcium while sparing magnesium, selectively blocking classical activation. The CH50 assay, in contrast, uses buffers that supply both ions, preserving the full classical cascade.
Common Pitfalls and Limitations
- Functional screening only: CH50 tells you if the pathway works, not which component is missing. Low values always require follow-up with specific immunoassays.
- Sample stability: Complement proteins are labile; improper serum storage or repeated freeze-thaw cycles can artificially depress CH50 values.
- Standardization challenges: Reagent variability—especially hemolysin potency and erythrocyte stability—can shift results between lots. Robust calibrators and internal controls are essential.
- Cannot detect all deficiencies: Rare cases of functional deficiencies with normal protein levels (e.g., dysfunctional C1 inhibitor) may still yield abnormal CH50, but interpretation requires clinical correlation.
- Interference from complement consumption: Acute-phase conditions or immune complex diseases may consume complement in vivo, lowering CH50 without a primary genetic deficiency.
How to Apply This to Your Assay Development or Clinical Practice
Choose your approach based on your primary goal:
- If your primary focus is developing a robust IVD CH50 kit: Source well-characterized hemolysin and stabilized sensitized erythrocytes, pair with a reference calibrator for 50% lysis normalization, and include a control serum with known CH50 range to monitor reagent lot consistency.
- If your primary focus is screening patients for complement deficiency: Always run CH50 and AH50 in parallel to narrow the differential, and confirm any low result with targeted quantitative assays for individual components (e.g., C3, C4) measured in fresh or frozen serum.
- If your primary focus is troubleshooting a low CH50 result: First verify sample integrity (no hemolysis, proper storage), then re-test with fresh serum to rule out in vitro consumption; use the CH50/AH50 pattern to guide reflex testing toward early classical components or terminal pathway proteins.
The CH50 test remains a cornerstone of complement diagnostics—a simple principle, a handful of reagents, and a clear window into the functional power of humoral immunity.
Summary Table:
| Aspect | Key Details |
|---|---|
| Biological Principle | Measures total classical complement activity (C1–C9) via MAC-mediated osmotic lysis of target cells. |
| Core Reagents | Antibody-sensitized sheep erythrocytes (EA complexes) and patient serum (complement source). |
| Assay Endpoint | 50% hemolysis of target erythrocytes, quantified spectrophotometrically at 412 nm. |
| Required Cations | Calcium (Ca²⁺) and Magnesium (Mg²⁺) for classical pathway assembly. |
| Diagnostic Pattern | Low CH50 + Normal AH50 indicates early classical component deficiency (C1, C4, C2). |
Are you developing or scaling complement pathway diagnostic assays? CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to premium IVD raw materials, technical services, and expert consulting—covering every stage from concept to clinic.
Contact CamelBio today to streamline your assay formulation and ensure consistent reagent quality.